<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03025698</url>
  </required_header>
  <id_info>
    <org_study_id>CETB115E2201</org_study_id>
    <nct_id>NCT03025698</nct_id>
  </id_info>
  <brief_title>A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia</brief_title>
  <official_title>A Phase II, Open-label, Non-controlled, Intra-patient Dose-escalation Study to Characterize the Pharmacokinetics After Oral Administration of Eltrombopag in Pediatric Patients With Refractory, Relapsed or Treatment Naive Severe Aplastic Anemia or Recurrent Aplastic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, open label, multi-center, intra-patient dose escalation study to&#xD;
      characterize the pharmacokinetics after oral administration of eltrombopag in combination&#xD;
      with immunosuppressive therapy in pediatric patients with previously untreated or&#xD;
      relapsed/refractory severe aplastic anemia or recurrent aplastic anemia.&#xD;
&#xD;
      All patients will be treated with eltrombopag for the 26-week Treatment Period, followed by a&#xD;
      52-week Follow-Up Period. Patients who have been previously untreated with immunosuppressive&#xD;
      therapy will be treated according to the standard of care, hATG/cyclosporine, in addition to&#xD;
      eltrombopag. Patients with relapsed/refractory SAA or recurrent AA will be enrolled into one&#xD;
      of two treatment options: hATG/cyclosporine plus eltrombopag or cyclosporine plus&#xD;
      eltrombopag, depending on prior treatment with immunosuppressive therapy.&#xD;
&#xD;
      After initiating treatment with eltrombopag, patients will have their dose assessed and&#xD;
      modified as tolerated, until the targeted platelet count or maximum dose is achieved.&#xD;
      Pharmacokinetic assessments will be performed at time points intended to capture steady state&#xD;
      PK of the starting dose and highest dose achieved.&#xD;
&#xD;
      Upon completion of the Treatment and Follow-Up Periods, all patients will be offered the&#xD;
      opportunity to enroll in an additional 3 year Long Term Follow-Up Period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 30, 2017</start_date>
  <completion_date type="Anticipated">May 26, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 24, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eltrombopag PK parameter: AUCtau</measure>
    <time_frame>2 weeks and 11 weeks after dose initiation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Eltrombopag PK parameter: Cmax</measure>
    <time_frame>2 weeks and 11 weeks after dose initiation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Eltrombopag PK parameter: Ctrough</measure>
    <time_frame>2 weeks and 11 weeks after dose initiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with an overall response (OR)</measure>
    <time_frame>Week 12, Week 26, Week 52, and Week 78.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a platelet response.</measure>
    <time_frame>Week 12, Week 26, Week 52, and Week 78.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clonal chromosomal population in bone marrow, myelodysplasia by morphology or acute leukemia</measure>
    <time_frame>Week 12, Week 26, Week 52 and Week 78.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>Cohort A (Option 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A (option 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eltrombopag</intervention_name>
    <description>Tablet for oral use, once daily or Powder for oral suspension (PfOS), once daily</description>
    <arm_group_label>Cohort A (Option 1)</arm_group_label>
    <arm_group_label>Cohort A (option 2)</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hATG</intervention_name>
    <description>Horse ATG (ATGAM) (hATG) is not considered an investigational medicinal product (IMP)</description>
    <arm_group_label>Cohort A (Option 1)</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CsA</intervention_name>
    <description>Cyclosporine (CsA) will be by supplied as either oral capsules or oral solution, administered twice a day</description>
    <arm_group_label>Cohort A (Option 1)</arm_group_label>
    <arm_group_label>Cohort A (option 2)</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For Cohort A patients:&#xD;
&#xD;
          1. History of prior diagnosis of SAA,&#xD;
&#xD;
          2. Diagnosis of relapsed/refractory SAA or recurrent AA following treatment for SAA, as&#xD;
             per Section 5.1. Patients with recurrent AA (e.g., losing their response) are exempt&#xD;
             from meeting the diagnostic criteria for SAA relapse at the time of study enrollment,&#xD;
             but must have been previously diagnosed with SAA.&#xD;
&#xD;
          3. Agree to concurrent eltrombopag treatment with appropriate, investigator-selected IST&#xD;
             with either hATG + CsA or CsA.&#xD;
&#xD;
             For Cohort B patients:&#xD;
&#xD;
          4. Diagnosis of SAA at time of enrollment.&#xD;
&#xD;
          5. Patients must not have been previously treated with IST, and must meet all criteria as&#xD;
             described in Table 5-1.&#xD;
&#xD;
          6. Patients must agree to treatment with hATG + CsA concurrent with eltrombopag.&#xD;
&#xD;
             All patients eligible for inclusion in this study must meet all of the following&#xD;
             criteria:&#xD;
&#xD;
          7. Age 1 to &lt;18 years.&#xD;
&#xD;
          8. Assessments to rule out congenital/inherited bone marrow failure syndromes and other&#xD;
             causes of immune-mediated pancytopenia, which may be treated with transplant, must be&#xD;
             completed prior to enrollment.&#xD;
&#xD;
          9. Hematopoietic stem cell transplantation (HSCT) is not suitable or available as a&#xD;
             treatment option or has been refused by the patient. (Candidacy for HSCT will be&#xD;
             determined as per local practices or national guidelines.)&#xD;
&#xD;
         10. Bone marrow aspirate and biopsy at any time during the 4 weeks prior to first dose of&#xD;
             eltrombopag.&#xD;
&#xD;
        12. Performance status score: Karnofsky ≥50 for patients 16 years of age and older or&#xD;
        Lansky ≥50 for patients below 16 years of age.&#xD;
&#xD;
        15. Written informed consent must be signed by a parent or legal guardian prior to&#xD;
        initiation of any study specific procedure.&#xD;
&#xD;
        16. Normal karyotype within 4 weeks prior to first dose of eltrombopag. If there are&#xD;
        insufficient metaphases (&lt; 10) to determine karyotype, a repeat marrow aspirate is&#xD;
        required. If upon repeat bone marrow aspirate, the number of metaphases is insufficient (&lt;&#xD;
        10), then FISH probes performed in marrow aspirate as per protocol must be normal.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        2. Prior and/or active medical history of:&#xD;
&#xD;
          -  Fanconi anemia (via chromosome breakage test or growth arrest by flow cytometry)&#xD;
&#xD;
          -  Other known underlying inherited marrow failure syndrome (such as but not limited to&#xD;
             Dyskeratosis Congenita, Congenital Amegakaryocytic Thrombocytopenia, or&#xD;
             Shwachman-Diamond Syndrome).&#xD;
&#xD;
          -  Symptomatic Paroxysmal Nocturnal Hemoglobinuria (PNH) and/or PNH clones &gt;50% of WBC or&#xD;
             RBC at time of enrollment.&#xD;
&#xD;
          -  Any cytogenetic abnormalities by karyotyping or FISH.&#xD;
&#xD;
          -  Myelodysplastic syndrome (MDS)&#xD;
&#xD;
          -  Other known or suspected underlying primary immunodeficiency&#xD;
&#xD;
          -  Any malignancy 3. Active infection not responding to appropriate therapy. 4. Prior&#xD;
             eltrombopag or other thrombopoietin receptor (TPO-R) agonist treatment for at least 2&#xD;
             months and a lack of response.&#xD;
&#xD;
             5. Have any of the following out-of-range laboratory values:&#xD;
&#xD;
          -  Serum Creatinine &gt;2.5 × upper limit of normal (ULN),&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt;3 × ULN. 6.&#xD;
             Concurrent participation in an investigational study within 30 days prior to&#xD;
             enrollment or within 5-half-lives of the investigational product, whichever is longer.&#xD;
             Note: a parallel enrollment in a registry for patients with SAA or AA is acceptable.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix Children's Hospital SC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Childrens Hospital SC</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aflac Cancer and Blood Disorders Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann and Robert H Lurie Childrens Hospital of Chicago SC</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University SC Riley Children's Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Boston SC</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System SC</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center SC-2</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center SC</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Cleveland Clinic (5)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer and Hematology Center SC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>117198</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sain Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok noi</city>
        <state>Bangkok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Khon Kaen</city>
        <state>THA</state>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 12, 2017</study_first_submitted>
  <study_first_submitted_qc>January 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2017</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Eltrombopag</keyword>
  <keyword>hATG</keyword>
  <keyword>CsA</keyword>
  <keyword>previously untreated or relapsed severe aplastic anemia</keyword>
  <keyword>recurrent aplastic anemia</keyword>
  <keyword>Severe aplastic anemia</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Immunosuppressive therapy</keyword>
  <keyword>ETB115</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

